| Literature DB >> 25339362 |
Hao Xu1, Nancy J Wandersee2, YiHe Guo3, Deron W Jones4, Sandra L Holzhauer5, Madelyn S Hanson6, Evans Machogu7, David C Brousseau8, Neil Hogg9, John C Densmore1, Sushma Kaul4, Cheryl A Hillery2, Kirkwood A Pritchard10.
Abstract
High mobility group box 1 (HMGB1) is a chromatin-binding protein that maintains DNA structure. On cellular activation or injury, HMGB1 is released from activated immune cells or necrotic tissues and acts as a damage-associated molecular pattern to activate Toll-like receptor 4 (TLR4). Little is known concerning HMGB1 release and TLR4 activity and their role in the pathology of inflammation of sickle cell disease (SCD). Circulating HMGB1 levels were increased in both humans and mice with SCD compared with controls. Furthermore, sickle plasma increased HMGB1-dependent TLR4 activity compared with control plasma. HMGB1 levels were further increased during acute sickling events (vasoocclusive crises in humans or hypoxia/reoxygenation injury in mice). Anti-HMGB1 neutralizing antibodies reduced the majority of sickle plasma-induced TLR4 activity both in vitro and in vivo. These findings show that HMGB1 is the major TLR4 ligand in SCD and likely plays a critical role in SCD-mediated inflammation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25339362 PMCID: PMC4271182 DOI: 10.1182/blood-2014-04-560813
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113